Rapid Therapeutic Science Laboratories, Inc.
RTSL
$0.0074
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.85% | 203.62% | |||
| Depreciation & Amortization | 0.00% | 110.38% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -78.43% | 460.07% | |||
| Operating Income | 78.43% | -460.07% | |||
| Income Before Tax | -75.74% | 291.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -75.74% | 291.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -75.74% | 291.21% | |||
| EBIT | 78.43% | -460.07% | |||
| EBITDA | 83.53% | -377.18% | |||
| EPS Basic | -76.67% | 280.95% | |||
| Normalized Basic EPS | -76.67% | 284.62% | |||
| EPS Diluted | -76.67% | 280.95% | |||
| Normalized Diluted EPS | -76.67% | 284.62% | |||
| Average Basic Shares Outstanding | 4.24% | 2.97% | |||
| Average Diluted Shares Outstanding | 4.24% | 2.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||